HEARTCARE-B (06609) shares surged 11.27% during intraday trading, as investors eagerly anticipate positive interim results. The stock's significant uptick comes ahead of a crucial board meeting scheduled for the same day to review and approve the company's financial performance for the first half of 2025.

The dramatic rise in share price is largely attributed to the company's recent announcement of an expected turnaround from loss to profit. HEARTCARE-B has projected a net profit attributable to shareholders of no less than RMB 40 million for the first six months of 2025, signaling a substantial improvement in its financial health.

Several factors contribute to this positive outlook, including increased revenue from newly launched hemorrhagic stroke treatment devices and acute ischemic stroke treatment products. The company also cites effective cost control measures in sales and administration, as well as reduced research and development expenditures due to changes in project development stages. Additionally, HEARTCARE-B reports higher fair value gains on financial assets measured at fair value through profit or loss, further bolstering its financial position. As the market digests this promising forecast, investors appear to be positioning themselves ahead of the official interim results announcement.